Compare Mesoblast Limited (MESO) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs TotalEnergies SE — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while TotalEnergies SE trades at $86.59 (market cap $187.35B). The key difference: TotalEnergies SE is far larger — about 103.5× Mesoblast Limited's market cap, and TotalEnergies SE pays a 5.03% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and TotalEnergies SE for 90 Days on average.
| MESO | TTE | |
|---|---|---|
Market Cap | $1.81B | $187.35B |
Volume | 240,620 | 1,924,317 |
Sector | Health | Energy |
52-Week High | $20.96 | $93.60 |
52-Week Low | $13.19 | $57.39 |
Typical Hold Time | 14 Days | 90 Days |
Enterprise Value | $1.89B | $218.34B |
Dividend Yield | — | 5.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
TotalEnergies (TTE) trades at $86.02, up 2.43% with strong earnings beats in Q1 and Q2 2026. The stock shows attractive valuation metrics with P/E of 10.54 and P/S of 0.94, while maintaining solid profitability with 9.08% net margin. Recent news highlights $10 billion Argentina investment and strategic growth plans through 2030, though technical indicators signal bearish momentum with key support at $83-84 levels.
TTE presents value opportunity with discounted valuation and dividend growth strategy, but faces headwinds from declining revenue trends and bearish technical setup. The 17% upside to consensus price target of $95.33 and 55.88% analyst buy rating support bullish case, though investors should monitor oil price volatility and execution of new investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
